TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05935384

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Guardant360
Description: Guardant360 is a qualitative next generation sequencing (NGS)-based in vitro diagnostic device for detection of single nucleotide variants (SNVs), insertions and deletions (indels), copy number amplifications (CNAs), and fusions in genes frequently mutated in cancer, using circulating cell-free DNA (cfDNA) obtained from the plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes.
Study: NCT04473235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Literacy training
Description: Teaching adults how to read and write using the analytical and phonemic method

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Literacy training
Description: Attending classes in geography, history, sciences, without receiving the specific training in literacy
Study: NCT06165458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel + violet LED
Description: Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by violet LED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel + blue LED
Description: Tooth whitening with 6% hydrogen peroxide gel (Lase Peroxide Lite, DMC, São Carlos, Brazil) activated by blue LED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel + violet LED
Description: Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by violet LED

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide gel + blue LED
Description: Tooth whitening with 35% hydrogen peroxide gel (Lase Peroxide Sensy, DMC, São Carlos, Brazil) activated by blue LED
Study: NCT05049083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: New Process SHR2554 tablet、Former Process SHR2554 tablet
Description: New Process, 350 mg SHR2554 tablets on study day 1 - Former Process, 350 mg SHR2554 tablets on study day 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Former Process SHR2554 tablet、New Process SHR2554 tablet
Description: Former Process, 350 mg SHR2554 tablets on study day 1 - New Process, 350 mg SHR2554 tablets on study day 8
Study: NCT05370183

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperambulatory tenotomy
Description: Using mini-optics a minimally invasive device, hypermabulatory tenotomy is performed in consultation, with a local anethesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operating room tenotomy
Description: Operating room tenotomy is performed according standard practice, with general anesthesia.
Study: NCT04760184

Intervention type: OTHER
Intervention: Autologous stem cell transplantation
Description: The study will describe the implications of COVID-19 infection following autologous stem cell transplantation
Study: NCT04684654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days
Study: NCT05128422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Description: it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours.This therapy should begin in the emergency room as early as possible when patients meet the inclusion criteria and are randomized to the experimental group
Study: NCT04684654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986325
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986325
Description: Specified dose on specified days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BMS-986325
Description: Specified dose on specified days
Study: NCT05320939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 MG
Description: 30 subjects (≥ 300 eosinophils/ul) will receive mepolizumab 100 mg subcutaneously every 4 weeks for 5 complete doses.
Study: NCT04730895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral 13 cis retinoic acid
Description: Dose of 0.5 mg/kg/day in 2 divided doses orally for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid
Description: Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases froms 0.2 mg/kg/day to 4 mg/kg/day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 13 cis retinoic acid doses orally in combination with spike protein based vaccine
Description: Dose of 13 cis retinoic acid (0.5 mg/kg/day in 2 divided doses orally for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aerosolized 13 cis retinoic acid in combination with spike protein based vaccine
Description: Dose of Aerosolized 13 cis retinoic acid in gradual in 2 divided doses increases from 0.2 mg/kg/day to 4 mg/kg/day for 14 days and also, participants will receive two doses of 5-7.5x10\^10 vp spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine in deltoid of non-dominant arm, 28 days apart

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Biological: spike protein based vaccine such as ChAdOx1 nCoV-19 vaccine
Description: Dose of 5-7.5x10\^10vp of spike protein based vaccine such as ChAdOx1 nCoV-19 in deltoid of non-dominant arm, 28 days apart
Study: NCT05823142

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CB Sleep
Description: The CB-sleep intervention is a cognitive behavioral intervention guided by principles and practices from motivational interviewing and the psychology of behavior change, primarily drawing on self-efficacy and action planning theory. The goals of CB-sleep are for participants to achieve adequate sleep duration (7-9 hours per night), adequate sleep efficiency (≥ 85%), and regular sleep timing (\<60-minute differences in bed and wake times). The intervention components include improving sleep knowledge (hygiene), developing a nightly routine, addressing competing activities, modifying environmental conditions, lifestyle (avoiding caffeine and vigorous exercise before bed), technology (limiting or avoiding screens for at least one hour before bed), basic stress-management (progressive muscle relaxation and guided imagery), and self- monitoring.
Study: NCT05376917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss CT Asphina / Zeiss CT Asphina
Description: Monovision with refractive target of -1.50D on the dominated eye

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss AT Lara/ Zeiss AT Lisa Tri
Description: Zeiss AT Lara (dominant eye) / Zeiss AT Lisa Tri (non-dominant eye)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss CT Asphina/ Zeiss AT Lara
Description: Zeiss CT Asphina/ Zeiss AT Lara (non-dominant eye)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zeiss AT Lara / Zeiss AT Lara
Description: Micromonovision with refractive target of -0.75D on the non-dominant eye
Study: NCT05152381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT05069701

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SVV test
Description: SVV test will be done with virtual reality glasses.
Study: NCT05426200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Patients will work with a health coach by telephone for up to 12 sessions over a 12-16 week period.
Study: NCT05962008

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHAPS® product
Description: Take 4 capsules per day after breakfast with warm water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: BioPS® product
Description: Take 4 capsules per day after breakfast with warm water.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 4 capsules per day after breakfast with warm water.
Study: NCT04820751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproheptadine Hydrochloride 4 MG
Description: Cyproheptadine associated to standard care
Study: NCT06227130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindYou
Description: A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MindYou
Description: A specially designed 6-week program incorporating meditation, mindfulness, and yoga, tailored to address specific challenges that resident doctors may face in their daily work.
Study: NCT05239689

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD38 CAR T-cells
Description: Drug: CD38 CAR T-cells Each subject receive CD38 CAR T-cells by intravenous infusion Other Name: CD38 CAR T-cells injection
Study: NCT05369806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive two-way SMS dialogue
Description: This study uses Mobile WACh, a human-computer hybrid system that enables two-way SMS communication and patient tracking, to provide consistent support to women and their infants during the peripartum period and 6 weeks into the baby's life. Women will receive automated SMS messages targeting the appropriate peripartum period and will have the capability to respond and spontaneously message a nurse based at the clinic. During pregnancy, automated SMS will be delivered weekly. Two weeks prior to the participant's estimated due date (EDD), daily messaging will begin, and will continue for two weeks after delivery is ascertained. Thereafter, SMS will be delivered every other day. Women who experience pregnancy or infant loss will be enrolled into an infant loss track. The NLP model will be applied to incoming participant messages. Those flagged as urgent by the model will be flagged within the SMS system, allowing study nurses to triage and appropriately respond to those messages.
Study: NCT04868630

Intervention type: DEVICE
Intervention: Pulsewave Health Monitor (PAD-2A) Device
Description: This is an observational study of the average breathing rate measurement of a non-invasive wrist cuff device. The purpose of this study is to calibrate the average breathing rate measurement of the Pulsewave Health Monitor (PAD-2A) wrist cuff device with the breathing rate measurement of a standard clinical capnography device. Additionally, we will also compare the average breathing rate measurement of the capnography device with other standard clinical respiratory devices (i.e. nasal pressure transducer, thermistor, and respiratory inductance plethysmography (RIP) belts of the chest and abdomen).
Study: NCT04950868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: They will initially be given 25 mg of quetiapine per day. The dose may be increased by 25-50 mg per week, to a maximum dose of 150 mg per day by week 6 of the study.
Study: NCT06331091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Home exercise are done at home without the supervision of a specialist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Home exercise are done at home without the supervision of a specialist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Supervised exercise is done under the supervision of a physiotherapist.
Study: NCT06170970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Description: solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Description: solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four weeks of oral placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four weeks of oral placebo
Study: NCT05863611

Intervention type: OTHER
Intervention: arms
Description: During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.

Intervention type: OTHER
Intervention: arms
Description: During the research, a questionnaire form (age, gender, educational status, etc.) in which your demographic information will be recorded for evaluation purposes and a consent form for participation in the study will be filled. Standardized Mini Mental Test will be applied. Then fragility will be evaluated with the Fried Fragility Index. Fall assessment will be assessed with the Fall Risk Self-Assessment Scale. Balance assessment will be made with the Tinetti Balance and Gait Assessment.
Study: NCT06368947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Play
Description: Therapeutic play sessions will be organized twice a week for 4 weeks during chemotherapy treatment for children diagnosed with acute lymphoblastic leukemia in the intervention group.
Study: NCT06657703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC022
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC022
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC022
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC022
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC022
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT04684927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-C System -Minimal invasive deformity correction system for the treatment of AIS
Description: A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS.
Study: NCT06657703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT06656156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation technique
Description: Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)
Study: NCT05439616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Capsules or Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules or Oral Solution
Study: NCT04704934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Study: NCT05564767

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. adolescentis Bif-038
Description: B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®
Description: Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule delivered orally once daily
Study: NCT05390216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial capsule decortication
Description: The anterior wall of the capsule was removed during the operation.
Study: NCT05857085

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector [Ozempic]
Description: GLP 1 agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: SGLT 2 inhibitor
Study: NCT06249620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inmunoferon
Description: The dosage regimen is two capsules (with the active ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dosage regimen is two capsules (with inert ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.